RAQUEL HERRERO: Open Payments
NPI 1871783514 · SAN JUAN, PR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$746 in 34 payments from 12 companies in 2025. Trend: 2023 $368 · 2024 $753 · 2025 $746
Food & beverage: $746
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $137 |
| Lundbeck LLC | 4 | $108 |
| E.R. Squibb & Sons, L.L.C. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 3 | $74 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $25 |
| Almatica Pharma LLC | 1 | $20 |
Products named: CAPLYTA, TRINTELLIX, REXULTI, COBENFY, SPRAVATO, AUSTEDO XR, INGREZZA, FANAPT.
Industry payments across PR — which companies pay providers there.
